Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2012
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experienceL R Molife, S Alam, D Olmos, et al.
British Journal of Cancer|September 16, 2010
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinomaJ M G Larkin, T R Ferguson, L M Pickering, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 12, 2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I UnitR Sundar, A Custodio, A Petruckevich, et al.
British Journal of Cancer|November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trialsE Geuna, D Roda, S Rafii, et al.
Oncology|August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsB Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
British Journal of Cancer|October 27, 2012
Association of creatine kinase and skin toxicity in phase I trials of anticancer agentsV Moreno Garcia, P Thavasu, M Blanco Codesido, et al.
Clinical and Translational Radiation Oncology|August 4, 2018
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumoursM T Dillon, Z Boylan, D Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG Saturno, F Lopes, I Niculescu-Duvaz, et al.
Pediatric Blood & Cancer|December 2, 2016
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemiaB Vormoor, G J Veal, M J Griffin, et al.
Pageof 3